Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04013984
Other study ID # POR-accupuncure
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2018
Est. completion date January 20, 2022

Study information

Verified date June 2023
Source Royan Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective randomized controlled trial is designed to investigate the effect of acupuncture on IVF/ICSI outcome in women with poor ovarian response. The study population consisted of all infertile women with a previous poor ovarian response who will undergo IVF/ICSI in Reproductive Biomedicine Research Center, Royan institute, Tehran Iran. To minimize the effect of ovarian stimulation protocol, a stratified randomization method according to ovarian stimulation protocols (GnRH agonist stopped and GnRH antagonist) is used.


Description:

Poor ovarian response (POR) is a challenging issue in assisted reproduction treatment. Different controlled ovarian hyperstimulation protocols and strategies have been used in this group of women to improve reproductive outcome, but the success rate still remains low. The aim of this study was to determine the effect of acupuncture during ovulation induction on the results of IVF / ICSI cycles in patients with POR diagnosis. The study was approved by the institutional review board. Written, informed consent will be obtained from each participant. Infertile women with a diagnosis of POR, who undergoing the IVF / ICSI cycle are assigned to four groups by stratified randomization method according to ovarian stimulation protocol. Before the starting the treatment cycle, patients will be randomized with sealed randomization envelopes. The random allocation is concealed from the physician performing the IVF/ICSI treatment cycle. All patients will receive acupuncture by the same physician (Dr.Salimi). In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons. There is no intervention in the control groups (B). Controlled ovarian stimulation for patients in both groups will be performed according the long stopped protocol. GnRH agonist (Buserelin, 0.5 mg), beginning on day 18 of the previous cycle will be used for down regulation and then will be stopped on the starting ovarian stimulation. Ovarian stimulation will be done with recombinant FSH and hMG (225 IU recombinant FSH (Gonal-F®; Serono Laboratories Ltd., Geneva, Switzerland) and 75 IU hMG (Menopur®; Ferring). The doses of gonadotropins were adjusted as ovarian response in the ultrasound monitoring. Ovulation was triggered with hCG (10,000 IU) when at least three follicles have a diameter of 18 mm with an adequate serum E2 concentration. In both group, transvaginal oocyte retrieval will be performed under ultrasound guidance 32-34 hours after hCG administration. Intracytoplasmic sperm injection will be performed for all metaphase II oocytes. Embryo transfer will be done under ultrasound guidance on day 3 for all patients. Primary consequences in this study are the total number of retrieved and MII oocytes and quality of the obtained embryos. Secondary outcomes are implantation and clinical pregnancy rates that confirmed by vaginal ultrasound (pregnancy sac and embryonic heart activity). The IVF/ICSI outcomes are compared in four groups. Data collection will be performed by using questionnaire to be filled as per the available records and laboratory results. Data analysis will be done through descriptive and perceptive statistical methods by using SPSS software version 20 for windows.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date January 20, 2022
Est. primary completion date January 20, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria: 1- Diagnosis of Poor ovarian response (POR), according to POSSEIDON group criteria (Group 3) Young patients (<35 years) with poor ovarian reserve prestimulation parameters (AFC <5, AMH<1.2 ng/mL). Exclusion Criteria: 1. Premature ovarian failure diagnosis. 2. Endometriosis grade III or IV. 3. Any contraindications to ovarian stimulation treatment. 4. Uterine infertility factor. 5. Previous history of ovarian surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Accupuncture
In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons

Locations

Country Name City State
Iran, Islamic Republic of Royan Institute Tehran

Sponsors (1)

Lead Sponsor Collaborator
Royan Institute

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total number of retrieved oocytes At the point of ovum pick-up, we can count total number of retrieved oocytes. Therefore, in one hour after ovum pick-up, outcome measurement will be possible. Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)
Primary Oocyte maturity At the point of ovum pick-up, we can count how many mature or immature oocytes were retrieved. Therefore, in one hour after ovum pick-up, outcome measurement will be possible. Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)
Primary Quality of obtained embryos Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure [ Time Frame: 3 days after intracytoplasmic sperm injection procedure ] Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure.The quality of embryos was graded from 1 to 3 under inverted microscope 3 days after intracytoplasmic sperm injection procedure. Embryos with even-sized blastomers and/or <5% fragments were classified as Grade 1 (good quality). Grade 2 embryos (moderate quality) had blastomeres with slightly-moderate size differences and/or 5-50% fragments. Grade 3 embryos (poor quality) had markedly different-sized blastomers and/or >50% fragments. 3 days after IVF/ICSI procedure
Secondary Implantation rate The ratio of total number of observed gestational sacs to total number of transferred embryos. 4 weeks after embryo transfer
Secondary Clinical pregnancy rate The observation of gestational sac with heart beat by using trans-vaginal ulterasound 4-6 weeks after embryo transfer
See also
  Status Clinical Trial Phase
Completed NCT03433768 - Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response N/A
Recruiting NCT05601193 - Ovarian PRP Injection in Women With POR N/A
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT03447184 - Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Completed NCT01816321 - Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial Phase 3
Recruiting NCT04310293 - Novel Therapy for Poor Responders Management N/A
Completed NCT05703308 - Menstrual Blood Stem Cells in Poor Ovarian Responders Phase 3
Terminated NCT00878124 - How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome N/A
Completed NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders Phase 2
Completed NCT01732068 - Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol Phase 2
Recruiting NCT06089395 - The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR) Early Phase 1
Recruiting NCT04717752 - A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve N/A
Recruiting NCT04024722 - Improving in Vitro Fertilization in Women With Poor Ovarian Response N/A
Completed NCT03994614 - the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR) N/A
Recruiting NCT03830697 - A Trial Study on Acupuncture Treatment of Poor Ovarian Response N/A
Recruiting NCT02801591 - Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET N/A
Recruiting NCT04273256 - Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT02993588 - Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders Phase 2/Phase 3
Recruiting NCT02418572 - Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Phase 3